CN113966332B — Cdk9抑制剂的多晶型物及其制法和用途
Assigned to Jinfang Pharmaceutical Technology Shanghai Co ltd · Expires 2024-07-30 · 2y expired
What this patent protects
本发明提供了一种CDK9抑制剂的多晶型物及其制法和用途。具体地，本发明公开了4‑(((4‑(5‑氯‑2‑(((1R,4r)‑4‑(((R)‑1‑甲氧基丙基‑2‑基)氨基)环己基)氨基)吡啶‑4‑基)噻唑‑2‑基)氨基)甲基)四氢‑2H‑吡喃‑4‑甲腈的马来酸盐或富马酸盐或它们的多晶型物及其应用。此外本发明还公开了含有上述物质的药物组合物及其应用。
USPTO Abstract
本发明提供了一种CDK9抑制剂的多晶型物及其制法和用途。具体地，本发明公开了4‑(((4‑(5‑氯‑2‑(((1R,4r)‑4‑(((R)‑1‑甲氧基丙基‑2‑基)氨基)环己基)氨基)吡啶‑4‑基)噻唑‑2‑基)氨基)甲基)四氢‑2H‑吡喃‑4‑甲腈的马来酸盐或富马酸盐或它们的多晶型物及其应用。此外本发明还公开了含有上述物质的药物组合物及其应用。
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.